Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Valneva, Vienna Airport (24/06/2024)

30.06.2024

Valneva: Valneva, an Austrian/French specialty vaccine company, today announced that Health Canada has approved IXCHIQ®, Valneva’s single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. This decision marks the second approval the Company has received for IXCHIQ® following approval from the U.S. Food and Drug Administration (FDA) in November 2023. The European Medicines Agency (EMA) also recently recommended marketing authorization of the vaccine in Europe, and a formal decision is expected in the third quarter of 2024. IXCHIQ® is the world’s only licensed chikungunya vaccine available to address this unmet medical need. Every year, over 50 million North Americans, of which approximately 7 million Canadians, travel to countries where chikungunya is endemic. Valneva began commercializing the vaccine in the U.S. this year and plans to sell first doses in Canada in the fourth quarter of 2024.
Valneva: weekly performance: 2.58%

Vienna Airport: The Supervisory Board of Flughafen Wien AG (Vienna Airport) unanimously reappointed the current members of the Management Board, Julian Jäger and Günther Ofner, to a new term of office beginning on 1 October 2025.  The current term of Julian Jäger was extended for an additional five-year period up until 30 September 2030, whereas the term of Günther Ofner was prolonged for three more years to 30 September 2028.
Flughafen Wien: weekly performance: 0.40%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (24/06/2024)


Partners









latest 21st Austria

21st Austria weekly - Valneva, Vienna Airport (24/06/2024)


30.06.2024, 1564 Zeichen



Valneva: Valneva, an Austrian/French specialty vaccine company, today announced that Health Canada has approved IXCHIQ®, Valneva’s single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. This decision marks the second approval the Company has received for IXCHIQ® following approval from the U.S. Food and Drug Administration (FDA) in November 2023. The European Medicines Agency (EMA) also recently recommended marketing authorization of the vaccine in Europe, and a formal decision is expected in the third quarter of 2024. IXCHIQ® is the world’s only licensed chikungunya vaccine available to address this unmet medical need. Every year, over 50 million North Americans, of which approximately 7 million Canadians, travel to countries where chikungunya is endemic. Valneva began commercializing the vaccine in the U.S. this year and plans to sell first doses in Canada in the fourth quarter of 2024.
Valneva: weekly performance: 2.58%

Vienna Airport: The Supervisory Board of Flughafen Wien AG (Vienna Airport) unanimously reappointed the current members of the Management Board, Julian Jäger and Günther Ofner, to a new term of office beginning on 1 October 2025.  The current term of Julian Jäger was extended for an additional five-year period up until 30 September 2030, whereas the term of Günther Ofner was prolonged for three more years to 30 September 2028.
Flughafen Wien: weekly performance: 0.40%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (24/06/2024)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Börsepeople im Podcast S16/01: Hannes Frech




 

Bildnachweis

Aktien auf dem Radar:Pierer Mobility, Warimpex, Semperit, Addiko Bank, Immofinanz, CA Immo, Rosgix, Linz Textil Holding, AT&S, Wienerberger, Mayr-Melnhof, Palfinger, SBO, EVN, Gurktaler AG Stamm, Kostad, UBM, Verbund, Wolford, Oberbank AG Stamm, DO&CO, Agrana, Amag, Flughafen Wien, OMV, Österreichische Post, RHI Magnesita, S Immo, Telekom Austria, Uniqa, VIG.


Random Partner

Evotec
Evotec ist ein Wirkstoffforschungs- und -entwicklungsunternehmen, das in Forschungsallianzen und Entwicklungspartnerschaften mit Pharma- und Biotechnologieunternehmen, akademischen Einrichtungen, Patientenorganisationen und Risikokapitalgesellschaften Ansätze zur Entwicklung neuer pharmazeutischer Produkte vorantreibt.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten